137 related articles for article (PubMed ID: 2218190)
1. Historical and methodological developments in clinical trials at the National Cancer Institute.
Gehan EA; Schneiderman MA
Stat Med; 1990 Aug; 9(8):871-80; discussion 903-6. PubMed ID: 2218190
[TBL] [Abstract][Full Text] [Related]
2. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute.
Halperin M; DeMets DL; Ware JH
Stat Med; 1990 Aug; 9(8):881-92; discussion 903-6. PubMed ID: 2218191
[TBL] [Abstract][Full Text] [Related]
3. Some historical and methodological developments in early clinical trials at the National Institutes of Health.
Greenhouse SW
Stat Med; 1990 Aug; 9(8):893-901; discussion 903-6. PubMed ID: 2218192
[TBL] [Abstract][Full Text] [Related]
4. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
5. The role of the biostatistician in cancer research.
Gehan EA
Biomed Pharmacother; 2001 Nov; 55(9-10):502-9. PubMed ID: 11769956
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine.
Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
[TBL] [Abstract][Full Text] [Related]
8. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
[TBL] [Abstract][Full Text] [Related]
9. Historical overview of the National Cancer Institute Fermentation Program.
Schepartz SA
Recent Results Cancer Res; 1978; 63():30-2. PubMed ID: 360332
[TBL] [Abstract][Full Text] [Related]
10. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
11. The Community Clinical Oncology Program (CCOP) story: review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987.
Frelick RW
J Clin Oncol; 1994 Aug; 12(8):1718-23. PubMed ID: 8040683
[TBL] [Abstract][Full Text] [Related]
12. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
Lichtman MA
Blood Cells Mol Dis; 2013 Feb; 50(2):119-30. PubMed ID: 23154039
[TBL] [Abstract][Full Text] [Related]
13. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
15. NCI Cooperative Clinical Trials Groups proceed with reorganization: new system aims to improve efficiency and address changing research needs.
Printz C
Cancer; 2013 Oct; 119(19):3423-4. PubMed ID: 24078257
[No Abstract] [Full Text] [Related]
16. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
17. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
18. A survey of monitoring practices in cancer clinical trials.
George SL
Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
[TBL] [Abstract][Full Text] [Related]
19. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.
Weiss GB; Bunce H; Hokanson JA
Control Clin Trials; 1983 Mar; 4(1):43-52. PubMed ID: 6851582
[TBL] [Abstract][Full Text] [Related]
20. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
